ClinicalTrials.gg
CompletedNCT03298984Updated Nov 15, 2023Results posted

Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).

A Phase 1 interventional study of Alvocidib and Cytarabine in Acute Myeloid Leukemia, sponsored by Sumitomo Pharma America, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-11-15.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing alvocidib in Leukemia, Myeloid, Acute — none open to participants now, none under way, none of them phase 3. alvocidib · Leukemia, Myeloid, Acute.

Enrollment
9th of 12
32 · median 41
Started
2017
the only one that year
Phase 1
5 of 12
none open now
Registered
9th of 12
by date
Lead sponsor
3 of 12
Sumitomo Pharma America, Inc.

Among the 12 studies testing alvocidib in Leukemia, Myeloid, Acute, this one is the 9th largest by enrollment, is the only one that started in 2017, is one of 5 in phase 1, and was the 9th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

None of the 12 studies testing alvocidib in Leukemia, Myeloid, Acute is open now. The open studies under Leukemia, Myeloid, Acute, anywhere →

About alvocidib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing alvocidib in Leukemia, Myeloid, Acute as a file.
02

Study summary

The purpose of this Phase I study is to determine the safety and tolerability including the maximum dose (MTD) and dose-limiting toxicities (DLTs) of alvocidib when administered over a range of doses on Days 1-3 followed by cytarabine/daunorubicin (7+3) on Days 5-11 in adults with newly diagnosed and previously untreated AML

Read the detailed description

Primary Objective:

  • To determine the safety and tolerability including the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of alvocidib when administered over a range of doses on Days 1-3 followed by cytarabine/daunorubicin (7+3) on Days 5-11 in adults with newly diagnosed and previously untreated AML

Secondary Objectives:

  • To observe patients for any evidence of antileukemic activity of alvocidib plus 7+3 using the 2017 ELN response criteria
  • To establish the Recommended Phase 2 Dose (RP2D) for future studies with alvocidib in combination with 7+3

Exploratory Objective:

  • To assess levels of minimal residual disease (MRD) using standardized techniques (ie, multiparametric flow cytometry [MPFC] and next generation sequencing [NGS] and evaluate other potential biomarkers including, but not limited to, MCL-1 dependency.
03

Conditions studied

  • Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • To be eligible for participation in the study, patients must meet all of the following inclusion criteria:

    1. Be between the ages of ≥18 and ≤65 years
    2. Have an established, confirmed diagnoses of AML by World Health Organization (WHO) criteria with ≥20% bone marrow blasts based on histology or flow cytometry
    3. Be newly diagnosed and previously untreated
    4. Have an (ECOG) performance status (PS) ≤2
    5. Have a serum creatinine level ≤1.8 mg/dL
    6. Have an (ALT) and aspartate aminotransferase (AST) level ≤5 times (ULN)
    7. Have a total level ≤2.0 mg/dL (unless secondary to Gilbert syndrome, hemolysis, or leukemia)
    8. Have a (LVEF) >45% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
    9. Be nonfertile or agree to use an adequate method of . Sexually active patients and their partners must use an effective method of contraception associated with a low failure rate prior to study entry, for the duration of study participation, and for at least 6 months after the last dose of study drug.
    10. Be able to comply with the requirements of the entire study.
    11. Provide written prior to any study related procedure. (In the event that the patient is re-screened for study participation or a protocol amendment alters the care of an ongoing patient, a new informed consent form must be signed.)

Exclusion criteria

Exclusion Criteria:

  • Patients meeting any one of these exclusion criteria will be prohibited from participating in this study.

    1. Received any previous treatment for AML
    2. Diagnosed with APL-M3 or CBF-AML
    3. Require concomitant chemotherapy, radiation therapy, or immunotherapy. Hydroxyurea is allowed up to the evening before starting (but not within 12 hours) of starting Induction therapy.
    4. Received >200 mg/m2 equivalents of daunorubicin
    5. Have a peripheral blast count of >30,000/mm3 (may use hydroxyurea as in #3 above)
    6. Have active central nervous system (CNS) leukemia
    7. Have evidence of uncontrolled disseminated intravascular coagulation
    8. Have an active, uncontrolled infection
    9. Have other life-threatening illness
    10. Have other active or diagnosed with other malignancies within the last 6 months, except nonmelanoma skin cancer or cervical intraepithelial neoplasia
    11. Have mental deficits and/or psychiatric history that may compromise the ability to give written or to comply with the study protocol.
    12. Are pregnant and/or nursing
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Alvocidib and Cytarabine/Daunorubicin

    The starting dose of alvocidib will be 20 mg/m2 as a 30-minute intravenous (IV) bolus followed by 30 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3 of Induction. Patients will have a one day drug holiday (Day 4) before initiation of the 7+3 regimen. Beginning on Day 5, cytarabine will be administered as a 100 mg/m2/day continuous IV infusion for seven consecutive days (Days 5-11) plus daunorubicin administered at a dosage of 60 mg/m2 IV on Days 5-7.

    Drug: Alvocidib · Drug: Cytarabine · Drug: Daunorubicin

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) of Alvocidib

    Determine the safety and tolerability including the maximum tolerated dose (MTD) of alvocidib when administered over a range of doses on Days 1-3 followed by Ara-c/daunorubicin (7+3) on Days 5-11 in adults with newly diagnosed and previously untreated AML

    Time frame: During the first cycle

  2. Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) of Alvocidib

    Determine the safety and tolerability including dose-limiting toxicities (DLTs) of alvocidib when administered over a range of doses on Days 1-3 followed by Ara-c/daunorubicin (7+3) on Days 5-11 in adults with newly diagnosed and previously untreated AML

    Time frame: During the first cycle

Secondary outcomes

  1. Antileukemic Activity of Alvocidib Plus 7+3 - Response to Treatment Based on 2017 ELN Response Criteria

    CR: Measurable residual disease is positive or unknown; BM blasts (bls) \<5%; no circulating bls and bls w/ Auer rods; no extramedullary disease; ANC \>1.0 x 109/L; platelets \>100 x 109/L. CRMRD-: CR w/ negativity genetic marker. CRi: CR except residual neutropenia or thrombocytopenia. MLFS: BM bls \<5%; no bls with Auer rods; no extramedullary disease; no hematologic recovery required. PR: all hematologic CR criteria; decrease (dec) BM bls % to 5-25%; dec pretreatment BM bls % by \>50%. SD: no CRMRD-/CR/CRi/PR/MLFS; PD criteria not met. PD: increase (inc) BM bls % and/or inc absolute bls in blood: 50% inc BM bls over baseline (\>15% point inc required in cases w/ \<30% bls at baseline or persistent BM bls % of \>70% over at least 3 months; without at least 100% improvement in ANC to absolute level \[\>0.5 x 109/L and/or platelet count to \>50 x 109/L non-transfused); or \>50% inc in peripheral bls to \>25 x 109/L (in the absence of differentiation syndrome); or new extramedullary disease.

    Time frame: Best response during duration of study

  2. Recommended Phase 2 Dose (RP2D) of Alvocidib in Combination With 7+3

    The dose at which \< 1 of 6 patients experience a DLT during Cycle 1 with the next higher dose having at least 2 of 3 to 6 patients experiencing a DLT during Cycle 1

    Time frame: During Cycle 1 beginning at 1st dose of study drug through Day 50 + or - 3 days

Other outcomes

  1. Minimal Residual Disease (MRD) Using Standardized Techniques

    Percentage of participants with a CRMRD- response at the end of Cycle 1

    Time frame: During duration of study

07

Results

Posted May 24, 2021

Participant flow

32 patients at 3 sites; Recruitment started 25Sep2017 Recruitment ended 20Mar2020

Participant flow — Overall Study
MilestoneAlvocidib 20/30 mg/m2Alvocidib 30/40 mg/m2Alvocidib 30/50 mg/m2Alvocidib 30/60 mg/m2
Started33323
Completed2218
Not completed11215
Withdrew: Physician decision1006
Withdrew: Lack of efficacy0114
Withdrew: Relapsed disease (following remission)0011
Withdrew: Adverse event0001
Withdrew: Death0002
Withdrew: Insurance company decision0001

Outcome measures

PrimaryMaximum Tolerated Dose (MTD) of Alvocidib

Determine the safety and tolerability including the maximum tolerated dose (MTD) of alvocidib when administered over a range of doses on Days 1-3 followed by Ara-c/daunorubicin (7+3) on Days 5-11 in adults with newly diagnosed and previously untreated AML

Time frame:
During the first cycle
Reported as:
Number · mg/m2
Maximum Tolerated Dose (MTD) of Alvocidib
mg/m2All Participants
Bolus30
IV infusion60
PrimaryNumber of Participants Who Experienced Dose Limiting Toxicities (DLTs) of Alvocidib

Determine the safety and tolerability including dose-limiting toxicities (DLTs) of alvocidib when administered over a range of doses on Days 1-3 followed by Ara-c/daunorubicin (7+3) on Days 5-11 in adults with newly diagnosed and previously untreated AML

Time frame:
During the first cycle
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) of Alvocidib
ParticipantsAlvocidib 20/30 mg/m2Alvocidib 30/40 mg/m2Alvocidib 30/50 mg/m2Alvocidib 30/60 mg/m2
Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) of Alvocidib0001
SecondaryAntileukemic Activity of Alvocidib Plus 7+3 - Response to Treatment Based on 2017 ELN Response Criteria

CR: Measurable residual disease is positive or unknown; BM blasts (bls) \<5%; no circulating bls and bls w/ Auer rods; no extramedullary disease; ANC \>1.0 x 109/L; platelets \>100 x 109/L. CRMRD-: CR w/ negativity genetic marker. CRi: CR except residual neutropenia or thrombocytopenia. MLFS: BM bls \<5%; no bls with Auer rods; no extramedullary disease; no hematologic recovery required. PR: all hematologic CR criteria; decrease (dec) BM bls % to 5-25%; dec pretreatment BM bls % by \>50%. SD: no CRMRD-/CR/CRi/PR/MLFS; PD criteria not met. PD: increase (inc) BM bls % and/or inc absolute bls in blood: 50% inc BM bls over baseline (\>15% point inc required in cases w/ \<30% bls at baseline or persistent BM bls % of \>70% over at least 3 months; without at least 100% improvement in ANC to absolute level \[\>0.5 x 109/L and/or platelet count to \>50 x 109/L non-transfused); or \>50% inc in peripheral bls to \>25 x 109/L (in the absence of differentiation syndrome); or new extramedullary disease.

Time frame:
Best response during duration of study
Reported as:
Number · participants
Antileukemic Activity of Alvocidib Plus 7+3 - Response to Treatment Based on 2017 ELN Response Criteria
participantsAlvocidib 20/30 mg/m2Alvocidib 30/40 mg/m2Alvocidib 30/50 mg/m2Alvocidib 30/60 mg/m2
Complete Remission MRD Negative (CRMRD-)2028
Complete Remission MRD Positive or Unknown (CR)1207
Partial Remission (PR)0101
Stable Disease0002
Progressive Disease (PD)0014
Not Evaluated0001
SecondaryRecommended Phase 2 Dose (RP2D) of Alvocidib in Combination With 7+3

The dose at which \< 1 of 6 patients experience a DLT during Cycle 1 with the next higher dose having at least 2 of 3 to 6 patients experiencing a DLT during Cycle 1

Time frame:
During Cycle 1 beginning at 1st dose of study drug through Day 50 + or - 3 days
Reported as:
Number · mg/m2
Recommended Phase 2 Dose (RP2D) of Alvocidib in Combination With 7+3
mg/m2All Participants
Bolus30
IV infusion60
Other pre-specifiedMinimal Residual Disease (MRD) Using Standardized Techniques

Percentage of participants with a CRMRD- response at the end of Cycle 1

Time frame:
During duration of study
Reported as:
Number · percentage of participants
Minimal Residual Disease (MRD) Using Standardized Techniques
percentage of participantsAlvocidib 20/30 mg/m2Alvocidib 30/40 mg/m2Alvocidib 30/50 mg/m2Alvocidib 30/60 mg/m2
Minimal Residual Disease (MRD) Using Standardized Techniques66.7066.734.8

Adverse events

Collected over Beginning at 1st dose of study drug through 30 days of the last administration of study drug. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alvocidib 20/30 mg/m2 (N=3)0/3 (0%)1/3 (33.3%)3/3 (100%)
Alvocidib 30/40 mg/m2 (N=3)0/3 (0%)0/3 (0%)3/3 (100%)
Alvocidib 30/50 mg/m2 (N=3)0/3 (0%)0/3 (0%)3/3 (100%)
Alvocidib 30/60 mg/m2 (N=23)2/23 (8.7%)5/23 (21.7%)23/23 (100%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventAlvocidib 20/30 mg/m2 (N=3)Alvocidib 30/40 mg/m2 (N=3)Alvocidib 30/50 mg/m2 (N=3)Alvocidib 30/60 mg/m2 (N=23)
Cardiogenic shockCardiac disorders1/30/30/30/23
FungaemiaInfections and infestations1/30/30/30/23
SepsisInfections and infestations1/30/30/31/23
Cytokine release syndromeImmune system disorders0/30/30/31/23
PneumoniaInfections and infestations0/30/30/31/23
Pneumonia fungalInfections and infestations0/30/30/31/23
Septic shockInfections and infestations0/30/30/31/23
Blood bilirubin increasedInvestigations0/30/30/31/23
Blood creatinine increasedInvestigations0/30/30/31/23
Tumour lysis syndromeMetabolism and nutrition disorders0/30/30/31/23
Most frequent other events
Showing 10 of 153
Most frequent other events
EventAlvocidib 20/30 mg/m2 (N=3)Alvocidib 30/40 mg/m2 (N=3)Alvocidib 30/50 mg/m2 (N=3)Alvocidib 30/60 mg/m2 (N=23)
Febrile neutropeniaBlood and lymphatic system disorders3/32/33/319/23
DiarrhoeaGastrointestinal disorders2/33/33/323/23
ConstipationGastrointestinal disorders0/32/33/35/23
Aspartate aminotransferase increasedInvestigations0/31/33/33/23
HypokalaemiaMetabolism and nutrition disorders3/32/33/316/23
CoughRespiratory, thoracic and mediastinal disorders1/33/31/33/23
NauseaGastrointestinal disorders1/32/32/317/23
AnaemiaBlood and lymphatic system disorders0/30/32/30/23
ProctalgiaGastrointestinal disorders2/30/30/31/23
Oedema peripheralGeneral disorders1/31/32/312/23

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Alvocidib 20/30 mg/m2Alvocidib 30/40 mg/m2Alvocidib 30/50 mg/m2Alvocidib 30/60 mg/m2Total
<=18 years00000
Between 18 and 65 years3332332
>=65 years00000
Sex: Female, Male
Sex: Female, Male(Participants)Alvocidib 20/30 mg/m2Alvocidib 30/40 mg/m2Alvocidib 30/50 mg/m2Alvocidib 30/60 mg/m2Total
Female221914
Male1121418
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Alvocidib 20/30 mg/m2Alvocidib 30/40 mg/m2Alvocidib 30/50 mg/m2Alvocidib 30/60 mg/m2Total
American Indian or Alaska Native10001
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American11125
White1122024
More than one race01012
Unknown or Not Reported00000
08

Study locations

3 sites
  • Sidney Kimmel Cancer Center at Johns Hopkins
    Baltimore, Maryland 21287, United States
  • Columbia University
    New York, New York 10032, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27599, United States
09

References and documents

Publications

  • Zeidner JF, Lee DJ, Frattini M, Fine GD, Costas J, Kolibaba K, Anthony SP, Bearss D, Smith BD. Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia. Clin Cancer Res. 2021 Jan 1;27(1):60-69. doi: 10.1158/1078-0432.CCR-20-2649. Epub 2020 Sep 30. PubMed 32998965 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Mar 2020, 29 months.

Results were first posted in May 2021, 1 year 2 months after primary completion.

Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's 29 months is below that.

Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2017
First posted
Oct 2, 2017
StartActual
Sep 25, 2017
Primary completionActual
Mar 20, 2020
CompletionActual
Mar 20, 2020
Results first posted
May 24, 2021
Last update
Nov 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03298984
Responsible party
Sponsor
First posted
Oct 2, 2017
Start date
Sep 25, 2017
Primary completion
Mar 20, 2020
Completion
Mar 20, 2020
Results posted
May 24, 2021
Last update
Nov 15, 2023

Study contacts

Stephen Anthony, DO
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alvocidib · Cytarabine · Daunorubicin

Start the discussion